Paper Details

  1. Home
  2. Paper Details

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.

Author: BellmuntJoaquim, ChoueiriToni K, DebiasiMarcio, FayAndre P, FranciniEdoardo, MalufFernando C, MoreiraRaphael B, NuzzoPier V, SchutzFabio A, VelascoGuillermo De

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This meta-analysis compared the risk of adverse events associated with abiraterone and enzalutamide, two drugs approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Paper Details　
Original Abstract of the Article :
Abiraterone and enzalutamide are currently approved for mCRPC patients. Both drugs have distinct mechanisms of action and may have different toxicity profile. There are limited data comparing the side effects of abiraterone and enzalutamide. We performed a meta-analysis of randomized controlled tria...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663621/

データ提供：米国国立医学図書館（NLM）

Comparing Side Effects of Abiraterone and Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

Abiraterone and enzalutamide are two drugs approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This meta-analysis of randomized controlled trials (RCTs) aims to compare the side effects profiles of these two drugs. The researchers investigate the relative risks of adverse events associated with each medication.

Different Side Effects Profiles for Abiraterone and Enzalutamide

The meta-analysis reveals distinct side effects profiles for abiraterone and enzalutamide. Abiraterone is associated with a higher risk of certain adverse events, such as hypokalemia, hypertension, and liver enzyme elevations. Enzalutamide, on the other hand, is more likely to cause fatigue, hot flashes, and musculoskeletal pain.

Navigating the Desert of Prostate Cancer Treatment

This research provides valuable information for clinicians treating mCRPC patients. It highlights the importance of considering the potential side effects of different medications and tailoring treatment to meet individual patient needs. Just as a camel must adapt its strategy to the specific challenges of the desert, healthcare providers must carefully weigh the benefits and risks of different treatment options.

Dr.Camel's Conclusion

This meta-analysis underscores the importance of comprehensive patient care and informed decision-making in prostate cancer treatment. It's a reminder that even in the vast and complex landscape of medical research, we can find valuable insights that guide us toward better outcomes for patients.
Date :
  1. Date Completed n.d.
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

29137449

DOI: Digital Object Identifier

PMC5663621

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.